STK11 and neoplasm: To ensure that the increased wasting observed in the setting of STK11/LKB1 loss-of-function variant tumors in immunocompetent hosts was not secondary to differential tumor size, we compared fat loss at the day 15 time point when the STK11/LKB1-silenced tumors had similar average tumor volumes compared to the day 18 time point for the control cohorts (Figure 5F).